2 research outputs found

    Efficacy of Breast Ultrasonography for Detection of Local, Regional, and Contralateral Recurrence of Breast Cancer

    Get PDF
    Purpose: Breast uttrasonography (US) is not recommended for recurrence monitoring after breast cancer surgery due to the lack of evidence for its advantage. The purpose of this study was to evaluate the usefulness of US for detecting local recurrence (LR), regional recurrence (RR) and contralateral breast cancer (CBC) in breast cancer patients during follow-up. Methods: The medical records of 5,833 breast cancer patients who underwent breast cancer surgery between January 2003 and December 2009 were reviewed retrospectively. Physical examination (PE), mammography (MMG), and US were done routinely to detect recurrences. Detection rate for locoregional and contralateral recurrence was compared between the three modalities. Results: During the follow-up period, 125 LR, 46 RR, 83 CBC, and 29 synchronous local and regional recurrences developed in 245 patients among the study population of 5,833 breast cancer patients. Median time to recurrence was 34.7 months. The recurrence detection rate was 51.9%, 43.5%, and 90.1% for PE, MMG, and US, respectively. Mean size of the recurrent lesions detected by US (1.57 cm) was smaller than that of PE (2.69 cm) and MMG (2.03 cm) (p=0.002). Conclusion: Breast US had higher recurrence detection rate for LA, RR, and CBC than PE or MMG after breast cancer surgery. μœ λ°©μ•”μ€ 2007λ…„ μš°λ¦¬λ‚˜λΌ μ—¬μ„± μ•” λ°œμƒλ₯  2μœ„(15.1%), λ°œμƒ ν™˜μž μˆ˜λŠ” 11,606λͺ…을 μ°¨μ§€ν•˜κ³  있고, μ—°κ°„ 6,6%의 높은 λ°œμƒλ₯ μ˜ 증가λ₯Ό 보이고 μžˆλ‹€.(1) λ˜ν•œ μ§€λ‚œ 10λ…„κ°„ κ΅­λ‚΄μ˜ μœ λ°©μ•” 치료 성적도 μ§€μ†μ μœΌλ‘œ κ°œμ„ λ˜μ–΄ 5λ…„ μƒμ‘΄μœ¨μ€ 77.9%μ—μ„œ 89.5%둜 11.5% μ¦κ°€ν•˜μ˜€λ‹€. μ΄λŸ¬ν•œ μœ λ³‘λ₯ μ˜ 증가와 μž₯κΈ° μƒμ‘΄μœ¨μ˜ ν–₯μƒμœΌλ‘œ 인해 1999λ…„ 이후 9λ…„ λ™μ•ˆ μœ λ³‘μž μˆ˜λ„ 68,136λͺ…(11.2%)으둜 λΉ λ₯΄κ²Œ μ¦κ°€ν•˜κ³  μžˆλ‹€.(1,2) μ΄λŸ¬ν•œ μœ λ°©μ•” λ°œμƒλ₯  증가와 사망λ₯  κ°μ†Œ 및 μœ λ°©μ•” 수술 ν›„ μž₯κΈ°μƒμ‘΄μžμ˜ 증가에 따라 동츑 유방 λ‚΄ μž¬λ°œμ„ ν¬ν•¨ν•œ κ΅­μ†Œμž¬λ°œκ³Ό λ°˜λŒ€μΈ‘ μœ λ°©μ•”μ΄ λ°œμƒν•˜λŠ” ν™˜μžμ˜ λΉˆλ„κ°€ 졜근 μ¦κ°€ν•˜κ³  μžˆλ‹€. National Surgical Adjuvant Breast and Bowel Project(NSABP) B-06의 경우 20λ…„μ˜ 좔적 κ΄€μ°°κΈ°κ°„ λ™μ•ˆ 14.3%의 동츑 유방 재발(ipsilateral breast tumor recurrence)을 λ³΄κ³ ν•˜μ˜€κ³ ,(3) 10λ…„μ˜ 좔적 κΈ°κ°„ λ™μ•ˆ 단독 κ΅­μ†Œ-ꡬ역 재발(locoregional recurrence)은 12.4%, 4κ°œμ›” 이내 μ „μ‹ μž¬λ°œμ„ λ™λ°˜ν•œ κ΅­μ†Œ-ꡬ역 μž¬λ°œμ€ 19.8% λ³΄κ³ λ˜μ—ˆλ‹€.(4) μœ λ°©μ•”μœΌλ‘œ μΉ˜λ£Œλ°›μ€ ν™˜μžμ—μ„œ λ°˜λŒ€μΈ‘ μœ λ°©μ•”(contralateral breast cancer)이 생길 ν™•λ₯ μ€ 2-11%둜 μœ λ°©μ•”μ— 걸리지 μ•Šμ€ 여성에 λΉ„ν•΄ 2-6배의 높은 μœ„ν—˜λ„λ₯Ό 가진닀.(5) 2008λ…„ ν•œκ΅­μœ λ°©μ•”ν•™νšŒ μœ λ°©μ•” μ§„λ£ŒκΆŒκ³ μ•ˆμ„ λΉ„λ‘―ν•˜μ—¬ μ„œκ΅¬μ˜ λ‹€μ–‘ν•œ μœ λ°©μ•” μ§„λ£ŒκΆŒκ³ μ•ˆμ—μ„œλŠ” κ΅­μ†Œ, ꡬ역, 그리고 λ°˜λŒ€μΈ‘ μœ λ°©μ•” μž¬λ°œμ„ 진단함에 μžˆμ–΄μ„œ 1λ…„λ§ˆλ‹€μ˜ 좔적 κ΄€μ°°κ³Ό ν•¨κ»˜ μœ λ°©μ΄¬μ˜μˆ μ„ μ‹œν–‰ν•˜λŠ” 것을 κΆŒκ³ ν•˜κ³  μžˆλ‹€. κ·ΈλŸ¬λ‚˜ μœ λ°©μ΄ˆμŒνŒŒλ‚˜ 유방 자기곡λͺ…μ˜μƒ λ“±μ˜ 좔가적 μ˜μƒκ²€μ‚¬μ˜ νš¨μš©μ€ 아직 λΆˆν™•μ‹€ν•˜μ—¬ κ³ μœ„ν—˜ ν™˜μžμ—μ„œ μ„ νƒμ μœΌλ‘œ μ‹œν–‰ν•˜λŠ” 것을 κΆŒν•˜κ³  μžˆλ‹€.(6-11)졜근 μ—¬λŸ¬ κ΅­λ‚΄μ™Έμ˜ μ—°κ΅¬μ—μ„œ μœ λ°©μ•” 수술 ν›„ κ΅­μ†Œμž¬λ°œμ΄λ‚˜ 앑와뢀 λ¦Όν”„μ ˆ μž¬λ°œμ„ μ‘°κΈ° λ°œκ²¬ν•˜λŠ” 데 μžˆμ–΄ 유방초음파의 잠재적 νš¨μš©μ„±μ΄ 보고되고 μžˆλ‹€.(12-15) 이에 λ³Έ μ—°κ΅¬μ—μ„œλŠ” μœ λ°©μ•”μ˜ κ΅­μ†Œ, ꡬ역, 그리고 λ°˜λŒ€μΈ‘ μœ λ°©μ•” μž¬λ°œμ„ μ§„λ‹¨ν•˜λŠ” 데 μžˆμ–΄μ„œ 유방 초음파의 μœ μš©μ„±μ„ λ‹¨μΌκΈ°κ΄€μ—μ„œ μˆ˜μˆ λ°›κ³  좔적 관찰받은 ν•œκ΅­μΈ μœ λ°©μ•” ν™˜μžκ΅°μ—μ„œ λΆ„μ„ν•΄λ³΄κ³ μž ν•˜μ˜€λ‹€.λ³Έ 논문은 2010년도 μ •λΆ€(κ΅μœ‘κ³Όν•™κΈ°μˆ λΆ€)의 μž¬μ›μœΌλ‘œ ν•œκ΅­μ—°κ΅¬μž¬λ‹¨μ˜ 기초 연ꡬ사업 지원을 λ°›μ•„ μˆ˜ν–‰λœ κ²ƒμž„(2010-0004148).Kelly KM, 2010, EUR RADIOL, V20, P2557, DOI 10.1007/s00330-010-1844-1Kim HJ, 2010, ANN SURG ONCOL, V17, P2670, DOI 10.1245/s10434-010-1087-zJung KW, 2010, J KOREAN MED SCI, V25, P1113, DOI 10.3346/jkms.2010.25.8.1113Aebi S, 2010, ANN ONCOL, V21, pv9, DOI 10.1093/annonc/mdq159Lehman CD, 2009, J NATL COMPR CANC NE, V7, P1109Houssami N, 2009, ANN ONCOL, V20, P1505, DOI 10.1093/annonc/mdp037Moon HJ, 2009, RADIOLOGY, V252, P673, DOI 10.1148/radiol.2523081977Yarnold J, 2009, CLIN ONCOL-UK, V21, P159, DOI 10.1016/j.clon.2008.12.008Kim MJ, 2009, AM J ROENTGENOL, V192, P221, DOI 10.2214/AJR.07.4048Montgomery DA, 2007, BRIT J CANCER, V96, P1802, DOI 10.1038/sj.bjc.6603815Yilmaz MH, 2007, DIAGN INTERV RADIOL, V13, P13Khatcheressian JL, 2006, J CLIN ONCOL, V24, P5091, DOI 10.1200/JCO.2006.08.8575Shin JH, 2005, J ULTRAS MED, V24, P643Taghian A, 2004, J CLIN ONCOL, V22, P4247, DOI 10.1200/JCO.2004.01.042Ciatto S, 2004, EUR J CANCER, V40, P1496, DOI 10.1016/j.ejca.2004.03.010Fisher B, 2002, NEW ENGL J MED, V347, P1233KIM SH, 2000, J KOREAN RADIOL SOC, V42, P1009Chen Y, 1999, CANCER EPIDEM BIOMAR, V8, P855GORDON PB, 1995, CANCER, V76, P626GIUSEPPETTI GM, 1989, RADIOL MED, V78, P339*NAT COMPR CANC NE, NCCN CLIN PRACT GUID*AM COLL RAD, ACR BREAST IM REP DA*NAT CANC INF CTR, CANC STAT*KOR BREAST CANC S, 3 BREAST CANC MAN RE
    corecore